Drug Profile
LGD 1324
Alternative Names: ALRT 324Latest Information Update: 18 Feb 1999
Price :
$50
*
At a glance
- Originator Ligand Pharmaceuticals
- Class Antihyperglycaemics; Obesity therapies
- Mechanism of Action Retinoid X receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Type 2 diabetes mellitus
Most Recent Events
- 18 Feb 1999 Discontinued-Preclinical for Type-2 diabetes mellitus in USA (Unknown route)
- 16 Dec 1997 Preclinical development for Type-2 diabetes mellitus in USA (Unknown route)